Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EZZ Life Science HoldingsASX:EZZ +3.23%49 Current Ratio is 6.57 as of Dec. 2025, which is 13% above its 10-year median of 5.79. GuruFocus rates ASX:EZZ with a GF Score™ of 49/100 and a GF Value™ of A$1.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, EZZ Life Science Holdings ranks better than 66.12% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. EZZ Life Science Holdings's current ratio for the quarter that ended in Dec. 2025 was 6.57.
EZZ Life Science Holdings has a current ratio of 6.57. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for EZZ Life Science Holdings's Current Ratio or its related term are showing as below:
ASX:EZZ'
s Current Ratio Range Over the Past 10 Years
Min: 3 Med: 5.79 Max: 6.74
Current: 6.57
During the past 6 years, EZZ Life Science Holdings's highest Current Ratio was 6.74. The lowest was 3.00. And the median was 5.79.
ASX:EZZ's Current Ratio is ranked better than 66.12% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs ASX:EZZ: 6.57
EZZ Life Science Holdings (ASX:EZZ) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
EZZ Life Science Holdings Current Ratio Related Terms
EZZ Life Science Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EZZ vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, EZZ Life Science Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings (ASX:EZZ) has a Current Ratio of 6.57 as of Dec. 2025. This is 13% above median its historical median of 5.79. Over the past decade, EZZ Life Science Holdings' Current Ratio has ranged from 3.00 to 6.74. According to the industry distribution chart, EZZ Life Science Holdings ranks #478 out of 1411 companies in the Biotechnology industry, placing it in the top 33.9%.
Is EZZ Life Science Holdings' Current Ratio too high?
EZZ Life Science Holdings' current Current Ratio of 6.57 is 13% above median its 10-year median of 5.79. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.74. The Biotechnology industry median Current Ratio is 3.85. EZZ Life Science Holdings' value of 6.57 is 70.6% above this industry median. Based on the distribution chart, EZZ Life Science Holdings ranks #478 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, EZZ Life Science Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #478 out of 1411 companies for Current Ratio. This puts EZZ Life Science Holdings in the upper half of its industry. The industry median Current Ratio is 3.85. EZZ Life Science Holdings' value of 6.57 is 70.6% above this benchmark. Historically, EZZ Life Science Holdings' own Current Ratio has ranged from 3.00 to 6.74 over the past decade. While the company's 10-year median is 5.79 vs. the industry median of 3.85, EZZ Life Science Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EZZ Life Science Holdings's current Current Ratio of 6.57 is 70.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EZZ Life Science Holdings's current Current Ratio is 6.57, which is 13% above median its own 10-year median of 5.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.45, compared to a current price of A$0.48 — trading 66.9% below its estimated fair value. The current Current Ratio is 6.57, which is 13% above median its 10-year median of 5.79 and 70.6% above the Biotechnology industry median of 3.85. EZZ Life Science Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current Current Ratio is 6.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.48 is trading 66.9% below its estimated GF Value™ of A$1.45.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
Current Ratio: 6.57 (13% above median its 10-year median of 5.79)
GF Value™: A$1.45 vs. price of A$0.48 (66.9% below fair value)
Industry Position: 70.6% above the Biotechnology median (#478 of 1411)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
49GF Score
Get the complete analysis for ASX:EZZ
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
